Signature‐oriented investigation of the efficacy of multicomponent drugs against heart failure

Abstract

Increasing attention has been paid to the application of precision medicine in heart failure (HF), and biomarker-based personalized medical care has shown great progress in HF management. Additionally, multicomponent drugs represented by traditional Chinese medicine (TCM) are demonstrating safety and efficacy in the management of HF. However, the potential mechanism is unclear, and the ambiguous clinical locations of TCM remain a hindrance to its extensive application. To meet this requirement, a precise investigation on the efficacy of multicomponent drugs against HF using the signature biomarkers-oriented approach was developed and applied to a conventional drug for cardiac disease, YiXinShu (YXS). On the basis of in vitro and in vivo efficacy evaluation of YXS against HF, and with the aid of proteomics and network pharmacology approaches, specific signatures regulated by YXS against HF were identified. YXS may show distinctive treatment features for those HF patients showing the elevation of fatty acid-binding protein 3 and cytoskeleton-associated protein 5, as well as other classic HF biomarkers. This study provides the first precise investigation of the efficacy of multicomponent drugs against HF and offers a practicable and low-cost approach for personalized management of HF.-Wei, J., Guo, F., Zhang, M., Xian, M., Wang, T., Gao, J., Wu, H., Song, L., Zhang, Y., Li, D., Yang, H., Huang, L. Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure.

Network Pharmacology-Based Investigation into the Mechanisms of Quyushengxin Formula for the Treatment of Ulcerative Colitis

“…TCM has the advantages of high treatment efficacy and low treatment cost and side effect in the treatment of several diseases, including UC in China for several thousands of years [32][33][34]. After preliminary screening based on ADME properties, 41 potential bioactive compounds of Quyushengxin were screened out.…”

Yixinshu capsule combined with conventional treatment for chronic heart failure

“…Yixinshu Capsule (YXS), a ShengMai-San-derived TCM formula, is widely used in Asia for the treatment of cardiovascular diseases as a conventional drug, [13,14] which has a potent effect on maintaining cardiac function by reducing oxidative stress injury and mitochondrial-mediated apoptosis. [12,13] And a new research [15] had demonstrated that Yixinshu capsule has distinctive treatment features against heart failure, which maybe particularly suitable for heart failure patients with exaltation of FABP3 and CKAP5. However, the quality of existing randomized controlled trials (RCTs) is uneven, and there are no interrelated meta-analysis and trial sequential analysis have been reported, so no definite conclusion has been drawn on this.…”

“…[13,14] A new research, based on efficacy evaluation in vitro ad in vivo, demonstrates that Yixinshu capsule has distinctive treatment features against heart failure, which maybe particularly suitable for heart failure patients with exaltation of FABP3 and CKAP5. [15] However, no interrelated meta-analysis and trial sequential analysis have been reported and no definite conclusion has been drawn on this.…”

Integrated UPLC-Q/TOF-MS Technique and MALDI-MS to Study of the Efficacy of YiXinshu Capsules Against Heart Failure in a Rat Model

“…Therefore, metabolomics offers a suitable way to understand disease pathogenesis and the mechanisms of YXSC from the standpoint of a metabolic evaluation. Furthermore, some specific molecular targets (e.g., fatty acid–binding protein 3 and cytoskeleton-associated protein 5), regulated by YXSC against HF, were identified by proteomic analysis in a study reported by us previously (Wei et al, 2019). However, the metabolic phenotype of HF as well as the metabolic regulation of YXSC against HF remains incomplete and therefore unclear.…”